NCT06746311View on ClinicalTrials.gov

This is a Phase 1 Study in Which Healthy Volunteers and Participants with Chronic HBV Infection Will Receive HT-101 or Placebo and Will Be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity

PHASE1CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

November 22, 2022

Primary Completion Date

May 13, 2024

Study Completion Date

June 17, 2024

Conditions
Chronic Hepatitis B
Interventions
DRUG

HT-101

Single dose of HT-101 administered subcutaneously.

DRUG

HT-101

Multiple dose of HT-101 administered subcutaneously.

DRUG

Placebo

Placebo, containing no active ingredient, administered subcutaneouly

Trial Locations (7)

100015

Beijing Ditan Hospital Capital Medical University, Beijing

100050

Beijing Friendship Hospital, Beijing

130021

The First Bethune Hospital of Jilin University, Changchun

133000

Yanbian University Hospital, Yanji

200083

Shanghai Public Health Clinical Center, Shanghai

221132

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

510515

Nanfang Hospital, Guangzhou

All Listed Sponsors
lead

Suzhou HepaThera Biotech Co., Ltd.

INDUSTRY